Wednesday September 27, 2017 01:07

Heathcare Press Release : 12 Sep 2017

Fiasp(R) Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Heathcare—12 Sep 17

Fiasp(R) (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional

More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Heathcare—12 Sep 17

A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments.

Unleashing the Power of the Latest Pharmaceutical Research for Simplified Global Healthcare Heathcare—12 Sep 17

Associated with over 1000 scientific societies and organizations, Conference Series is scheduled to organize pharmaceutical conferences in Europe, USA, and Asia Pacific with a view to unleash precious scientific findings for the benefit of

Merck Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Heathcare—12 Sep 17

- Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on